Investing.com - Financial Markets Worldwide

Kolon Life Science Inc (102940)

KOSDAQ
Currency in KRW
32,150
-500(-1.53%)
Closed·

102940 Financial Summary

Key Ratios

P/E Ratio-21.51
Price/Book1.58
Debt / Equity47.44%
Return on Equity-10.02%
Dividend Yield0.00%
EBITDA-13.21B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2009
31/12
2010
31/12
2011
31/12
2012
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa129,412.92165,485.31161,583.79124,639.03161,386.74
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa18,735.7637,103.8637,016.6812,296.0616,743.67
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-25,835.494,249.122,641.69-24,095.03-22,084.41
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-43,195.23-1,374.922,133.32-30,726.34-93,085.91
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa248,337.69234,658.31314,117.89309,435.55419,562.62
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa145,152.295,469.23109,577.51128,341.45206,255.2
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa57,957.1399,410.16167,723.25137,671.98149,337.5
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-12,554.24-25,820.88-26,124.44-15,475.5148,670.6
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-7,307.02-16,187.35-20,853.66-24,865.56-14,084.84
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa19,037.06-2,254.78-5,936.55-7,025.96-6,382.08
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-2,378.7230,949.145,457.6132,889.2824,778.89
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa9,087.2912,799.47-21,428.941,1904,937.04
* In Millions of KRW (except for per share items)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-120.00 / --
Revenue / Forecast
52.96B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Kolon Life Science's earnings for the latest quarter?

The Kolon Life Science EPS (TTM) is -1,629.22. Kolon Life Science reported sales of 52,958.60, net income of -1,486.41, and EPS of -120.00 for the latest quarter.

What was Kolon Life Science's net income for the latest quarter?

Kolon Life Science's net income for the latest quarter was -1,486.41.

How did Kolon Life Science's performance compare year-over-year in the latest quarter?

The company's revenue moved from 44,830.81 in the previous quarter to 52,958.60 in the latest quarter, and net income moved from 10,480.98 to -1,486.41 compared to the previous quarter.

What is Kolon Life Science's net profit margin on a TTM basis?

Kolon Life Science's trailing twelve months (TTM) net profit margin is -57.68%.

How does Kolon Life Science's debt to equity ratio compare to industry standards?

Kolon Life Science's total debt-to-equity ratio is 47.44%.

What is Kolon Life Science's return on investment on a TTM basis?

Kolon Life Science's trailing twelve months (TTM) return on investment (ROI) is -10.02%.

Did Kolon Life Science gain or lose cash last quarter?

In the latest quarter, Kolon Life Science's net change in cash was 10,185.86 million.

What were Kolon Life Science's total assets and liabilities in the latest quarter?

As of the latest quarter, Kolon Life Science reported total assets of 588,803.68 million and total liabilities of 218,666.24 million.

How has Kolon Life Science's total revenue grown this year?

Kolon Life Science's total revenue was 44,830.81 in the previous quarter and 52,958.60 in the latest quarter.

What is Kolon Life Science's gross margin on a TTM basis?

Kolon Life Science's trailing twelve months (TTM) gross margin is 15.31%.

What was Kolon Life Science's revenue per share for the latest quarter?

Kolon Life Science's revenue per share for the latest quarter was 14,657.45.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.